Related references
Note: Only part of the references are listed.The cancer stem cell niche(s): The crosstalk between glioma stem cells and their microenvironment
Alina Filatova et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2013)
Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
Tom Donnem et al.
CANCER MEDICINE (2013)
STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro
Haixiao Wang et al.
BMB REPORTS (2012)
Evolution and roles of stanniocalcin
B. H. Y. Yeung et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Sarah J. Conley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer on the Cardiovascular System
Babak Nazer et al.
CIRCULATION (2011)
Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
David Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The cancer stem cell: premises, promises and challenges
Hans Clevers
NATURE MEDICINE (2011)
Treatment of Metastatic Colorectal Cancer
Janine M. Davies et al.
SEMINARS IN ONCOLOGY (2011)
Clinical Significance of Stanniocalcin 2 as a Prognostic Marker in Gastric Cancer
Takehiko Yokobori et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics
Qun Lin et al.
CANCER BIOLOGY & THERAPY (2010)
Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia
Alice Y. S. Low et al.
EXPERIMENTAL CELL RESEARCH (2010)
Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells
Alice Y. S. Law et al.
EXPERIMENTAL CELL RESEARCH (2010)
Colon Cancer Stem Cells: Promise of Targeted Therapy
Matilde Todaro et al.
GASTROENTEROLOGY (2010)
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
Richard M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Hypoxia-Inducible Factors and the Response to Hypoxic Stress
Amar J. Majmundar et al.
MOLECULAR CELL (2010)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Oncogenic KRAS and BRAF Differentially Regulate Hypoxia-inducible Factor-1α and-2α in Colon Cancer
Hirotoshi Kikuchi et al.
CANCER RESEARCH (2009)
Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis
Emina H. Huang et al.
CANCER RESEARCH (2009)
Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer
Kenji Tamura et al.
CANCER SCIENCE (2009)
Identification of Stanniocalcin 2 as Prognostic Marker in Renal Cell Carcinoma
Hellmuth-A. Meyer et al.
EUROPEAN UROLOGY (2009)
Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma
Sonja Volland et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer
Keisuke Ieta et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery
W. Cacheux et al.
ANNALS OF ONCOLOGY (2008)
Tumor dormancy:: Elevated expression of stanniocalcins in late relapsing breast cancer
Kristiina Joensuu et al.
CANCER LETTERS (2008)
TSU68 Prevents Liver Metastasis of Colon Cancer Xenografts by Modulating the Premetastatic Niche
Masayoshi Yamamoto et al.
CANCER RESEARCH (2008)
Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells
Alice Y. S. Law et al.
EXPERIMENTAL CELL RESEARCH (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties
D Ito et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Mammalian stanniocalcins and cancer
ACM Chang et al.
ENDOCRINE-RELATED CANCER (2003)
Orthotopic implantation of a colon cancer xenograft induces high expression of cyclooxygenase-2
T Shoji et al.
CANCER LETTERS (2003)
In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors
P Mahy et al.
RADIOTHERAPY AND ONCOLOGY (2003)
Share Paper
